Health
Clinical trial testing efficacy of antibody against SARS-CoV-2 begins – Medical Xpress
The University of Chicago Medicine is launching a clinical trial to examine the potential of an antibody against the SARS-CoV-2 spike protein for treating COVID-19, the disease caused by the novel coronavirus.
The University of Chicago Medicine is launching a clinical trial to examine the potential of an antibody against the SARS-CoV-2 spike protein for treating COVID-19, the disease caused by the novel coronavirus.
For the BLAZE-1 trial, UChicago is recruiting 22 participants to be treated with the LY-CoV555 antibody developed by Eli Lilly and Company in collaboration with AbCellera. The antibody was first identified by scientists at the National Institute of Allergy and Infectious Diseases and AbCe…
-
General20 hours agoHundreds gather in Gin Gin at vigil for allegedly murdered teen Pheobe Bishop
-
Noosa News21 hours agoDaly Cherry-Evans set to be dropped as Maroons captain
-
Noosa News21 hours agoThe Story Bridge should serve as a warning – and an opportunity
-
Noosa News19 hours agoPheobe Bishop: Community mourns loss of murdered teenager